Fisher Asset Management LLC Acquires 957,907 Shares of Denali Therapeutics Inc. $DNLI

Fisher Asset Management LLC raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 58.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,589,403 shares of the company’s stock after purchasing an additional 957,907 shares during the period. Fisher Asset Management LLC’s holdings in Denali Therapeutics were worth $42,751,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the 2nd quarter valued at $26,000. Johnson Financial Group Inc. bought a new stake in Denali Therapeutics in the 3rd quarter valued at $29,000. State of Wyoming bought a new stake in Denali Therapeutics in the 2nd quarter valued at $29,000. Quarry LP bought a new stake in Denali Therapeutics in the 3rd quarter valued at $64,000. Finally, Assetmark Inc. increased its holdings in Denali Therapeutics by 31.8% in the 4th quarter. Assetmark Inc. now owns 5,187 shares of the company’s stock valued at $86,000 after buying an additional 1,250 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 4.0%

DNLI opened at $19.38 on Wednesday. The firm’s 50-day simple moving average is $19.72 and its 200-day simple moving average is $19.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28. Denali Therapeutics Inc. has a twelve month low of $12.58 and a twelve month high of $23.77. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of -6.73 and a beta of 0.99.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter in the prior year, the business posted ($0.78) earnings per share. Equities research analysts anticipate that Denali Therapeutics Inc. will post -2.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DNLI has been the topic of several analyst reports. Wall Street Zen raised shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Monday, April 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a report on Monday, March 2nd. Leerink Partners lowered their target price on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Finally, HC Wainwright upped their target price on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.25.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.